NewAmsterdam Pharma (NAMS) Cash from Investing Activities (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Cash from Investing Activities data on file, last reported at -$11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 503.12% year-over-year to -$11.5 million; the trailing twelve-month figure through Mar 2026 stood at -$189.3 million (down 217.54% YoY), and the FY2025 full-year result was -$174.9 million, down 178.32% from the prior year.
• Cash from Investing Activities improved to -$11.5 million in Q1 2026, from -$21.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $2.9 million in Q1 2025 to a low of -$159.1 million in Q2 2025.
• A 4-year average of -$19.2 million and a median of -$75000.0 in 2024 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities plunged 2072533.33% in 2024 and soared 3441.33% in 2025, its largest moves.
• Tracing NAMS's Cash from Investing Activities over 4 years: stood at -$3000.0 in 2023, then sank by 2072533.33% to -$62.2 million in 2024, then surged by 66.0% to -$21.1 million in 2025, then soared by 45.56% to -$11.5 million in 2026.
• Business Quant data shows NAMS's Cash from Investing Activities at -$11.5 million in Q1 2026, -$21.1 million in Q4 2025, and $2.5 million in Q3 2025.